Acrivon Therapeutics completes IPO and concurrent $5M private placement with Chione Limited

Acrivon Therapeutics, Inc.

Closed IPO and concurrent $5M private placement with Chione Limited on Nov 17, 2022.
Issued 400,000 unregistered shares at $12.50/share to Chione under Section 4(a)(2) exemption.
Filed amended certificate of incorporation and bylaws effective upon IPO closing.
Shares in private placement are subject to lock-up and transfer restrictions; no public offering registration.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Acrivon Therapeutics, Inc.: Amended and Restated Certificate of Incorporation filed in connection with IPO closing (effective 2022-11-17).

Change: charter amendment
Effective: 2022-11-17

Exact text from the filing

On November 17, 2022, Acrivon Therapeutics, Inc. (the “Company”) filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of its common stock (the “IPO”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Acrivon Therapeutics, Inc.: Amended and Restated Bylaws adopted in connection with IPO closing (effective 2022-11-17).

Change: bylaw amendment
Effective: 2022-11-17

Exact text from the filing

Effective as of November 17, 2022, the Company adopted Amended and Restated Bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.

View on SEC.gov

Browse all governance changes →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-287727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.